Get started
Author

Jens Schrezenmeier

Observed names: J. Schrezenmeier, J.-F. Schrezenmeier, J.F. Schrezenmeier, Jens F. Schrezenmeier, Jens Florian Schrezenmeier, Jens-Florian Schrezenmeier, Schrezenmeier, Jens Florian
Observed institutions: Max Delbrück Center, Wellcome/MRC Cambridge Stem Cell Institute, University of Cambridge, Humboldt-Universität zu Berlin, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Stiftung Charité, Freie Universität Berlin, Charité - Universitätsmedizin Berlin
ORCID: 0000-0001-5239-4513
Observed ORCID: 0000-0001-5239-4513
OpenAlex ID: A5075021493
Initiation of acute graft-versus-host disease by angiogenesis
2017 · Katarina Riesner, Yu Shi, et al. · Blood · 69
PDF
Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial
2022 · Claudia M. Denkinger, Maike Janssen, et al. · Nature Cancer · 61
PDF
Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas
2020 · Maurice Reimann, Jens Schrezenmeier, et al. · Blood · 59
Endothelial damage and dysfunction in acute graft-versus-host disease
2020 · Steffen Cordes, Zeinab Mokhtari, et al. · Haematologica · 58
PDF
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial
2025 · Simone Hoffmann, Eva Schrezenmeier, et al. · EBioMedicine · 22
Epigenetic dysregulation in acute myeloid leukemia
2025 · Jens Schrezenmeier, B.J.P. Huntly · Seminars in Hematology · 19
AML with complex karyotype: extreme genomic complexity revealed by combined long-read sequencing and Hi-C technology
2023 · Marius-Konstantin Klever, Eric Sträng, et al. · Blood Advances · 15
Therapy-related AML: long-term outcome in a large cohort of AML-patients with intensive and non-intensive therapy
2024 · Sophia Gross, Jana Ihlow, et al. · Blood Cancer Journal · 12
PDF
Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus–Positive Kidney Transplant Recipients
2018 · Eva Schrezenmeier, Friederike Hoffmann, et al. · Therapeutic Drug Monitoring · 6
Kidney Transplantation after Clearing Anti-HLA Antibodies with CD19 CAR T Cells
2026 · Jens Schrezenmeier, Hector Rincon-Arevalo, et al. · New England Journal of Medicine · 5
Anti-SARS-CoV-2 antibody containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19 via increased neutralizing antibody activity – a randomized clinical trial
2022 · C.M. Denkinger, M. Janssen, et al. · medRxiv · 4
PDF
Integration of Hi-C and Nanopore Sequencing for Structural Variant Analysis in AML with a Complex Karyotype: (Chromothripsis)²
2020 · Marius-Konstantin Klever, Eric Sträng, et al. · Blood · 3
Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients
2022 · Michael Heuser, Nouraldin Damrah, et al. · Blood · 2
S282: a Randomized Controlled Clinical Trial Demonstrates That Plasma From Convalescent and Vaccinated Donors Improves Outcome of Covid-19 in Patients With Hematological Disease, Cancer or Immunosuppression
2022 · C. Müller-Tidow, M. Janssen, et al. · HemaSphere · 2
Modeling the CNS Tropism of Diffuse Large B-Cell Lymphomas in Vivo
2015 · Maurice Reimann, Sven Masswig, et al. · Blood · 1
Single-cell dissection of stemness programs and transcriptional plasticity in pediatric acute myeloid leukemia relapse
2026 · Schrezenmeier, Jens Florian · Zenodo (CERN European Organization for Nuclear Research)
antiCD19_HLA
2026 · Schrezenmeier, Jens Florian · Zenodo (CERN European Organization for Nuclear Research)
antiCD19_CART_NTX_cross_integration
2026 · Schrezenmeier, Jens Florian · Zenodo (CERN European Organization for Nuclear Research)
Rapid and reproducible karyotyping with long-read sequencing in patients with AML
2026 · Michael Heuser, Anna Dolnik, et al. · Blood Advances
AML maturation stages associate with disease-permissive and immunosuppressive effects in newly diagnosed AML patients: An analysis at the single-cell level
2025 · Jana Ihlow, Jens Schrezenmeier, et al. · Blood
PDF
1142. Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trial
2022 · Claudia M Denkinger, Maike Janssen, et al. · Open Forum Infectious Diseases
Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients
2022 · Sophia Gross, Jana Ihlow, et al. · Blood
P456: a Long Read Sequencing and Crispr-cas9 Based Approach for Rapid Copy-number Alteration and Structural Variation Detection in Hematologic Malignancies
2022 · J. Schrezenmeier, J. E. Straeng, et al. · HemaSphere
Functional genomic investigation of the human aggressive lymphoma derived genetic lesions MYD88L265P, NFKBIZ, CARD11L244P, CD79BY196H and PD-L1 in a murine Eµ-myc lymphoma model
2019 · Schrezenmeier, Jens Florian · Refubium (Universitätsbibliothek der Freien Universität Berlin)
To016clinical Pharmacokinetics of Sofosbuvir and Daclatasvir in Kidney Transplant Recipients
2017 · Eva Schrezenmeier, Klemens Budde, et al. · Nephrology Dialysis Transplantation
Works count: 26
Citation count: 338
H-index: 8
I10-index: 8
Year
Topic
Type